What is the half-life of VK2735?
VK2735 has a reported half life of Long-acting; dosed once-weekly (subcutaneous) in trials, given subcutaneous (weekly) or oral (daily), both investigational. That is why it is typically dosed weekly (injectable) or once-daily (oral) in trials. A shorter half life means more frequent dosing to keep blood levels steady, a longer one lets you space doses further apart.
Quick facts
- Half-life: Long-acting; dosed once-weekly (subcutaneous) in trials
- Route: Subcutaneous (weekly) or oral (daily), both investigational
- Typical schedule: Weekly (injectable) or once-daily (oral) in trials
- Cycle length: Trial protocols ran 13 weeks; no established real-world cycle
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on VK2735
Last updated 2026-06-15.